FINWIRES · TerminalLIVE
FINWIRES

VVT Med社、ユニットの私募による第一段階の資金調達を完了

-- VVT Med(VVTM.V)は、以前発表した仲介業者を介さない私募増資の第1弾を完了し、総額最大300万ドルを調達したと水曜日に発表した。同社は、1ユニットあたり0.25ドルで4,262,654ユニットを発行し、総額106万5,000ドルを調達した。 各ユニットは、普通株式1株と普通株式購入権の半分で構成され、各購入権は発行日から2年間、1株あたり0.375ドルの行使価格で普通株式1株に転換可能である。 調達資金は、米国および世界における事業拡大、予想される需要に対応するための製品製造、運転資金、および一般的な企業ニーズに充当される予定であると述べ、第2弾の私募増資も追って完了する予定であると付け加えた。 同社の株式は4月20日にトロント証券取引所ベンチャー市場で0.23ドルで取引を終えた。

Related Articles

Asia

National Australia Bank Shares Down After Resolution of Union Court Proceedings

National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."

$ASX:NAB
Asia

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.

$ASX:CUV
Asia

XRF Scientific Completes Acquisition of Combustion Gas Analysis Business

XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.

$ASX:XRF